Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes

The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.

Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken with the determination of glucagon.

Inclusion Criteria:

• Type 1 diabetes
• Age >18 years
• HbA1c 6.5-8,5%

Exclusion Criteria:

• Pregnancy
• Lactation
• Acute infection
• Liver disease
• Treatment with cortisol